Skip to main content
Premium Trial:

Request an Annual Quote

Stock Talk

In a Q&A posted at Market Playground, AlphaNorth Asset Management Chief Investment Officer Steven Palmer tells The Life Sciences Report's George Mack that when it comes to pharma and biotech investments, "it is all about risk versus reward." For that reason, Palmer says he generally errs on the side of investing in established, later-stage companies. "I try to stay away from the private life sciences companies because that really implies they are much earlier stage. The earlier stage you go in biotech, the higher the risk," he tells Mack.

Mack then asks whether investing in a biotech that has yet to move its product into the clinic is a good idea. "We look for companies that are working on products that have huge market potential and situations that we view as lower risk," Palmer tells him. "We also prefer companies that have multiple products. I view biotech similar to mining companies actually. Whether it is exploration success or clinical success, the rewards can be dramatic."

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.